The effects of antihypertensive agents on the survival rate of polycystic kidney disease in Han:SPRD rats

Hypertension Research

Volumn 25, Issue 6, 2002, Pages 939-943

  Kanno, Yoshihiko ^a   Okada, Hirokazu ^a   Moriwaki, Kenshi ^a   Nagao, Shizuko ^b   Takahashi, Hisahide ^b   Suzuki, Hiromichi ^a  

^a SAITAMA MEDICAL UNIVERSITY   (Japan)

^b FUJITA HEALTH UNIVERSITY   (Japan)

Author keywords

Autosomal dominant polycystic kidney disease; Complication; Hypertension

Indexed keywords

AMLODIPINE; ANTIHYPERTENSIVE AGENT; BENAZEPRIL; PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; AUTOPSY; AUTOSOMAL DOMINANT DISORDER; BLOOD PRESSURE REGULATION; BODY WEIGHT; CONTROLLED STUDY; DISEASE CONTROL; DISEASE COURSE; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; HEREDITY; HYPERTENSION; KIDNEY PARENCHYMA; KIDNEY POLYCYSTIC DISEASE; MALE; MORTALITY; NONHUMAN; PATIENT CARE; PROTEIN URINE LEVEL; RAT; RAT STRAIN; SPONTANEOUSLY HYPERTENSIVE RAT; SURVIVAL RATE; TUMOR VOLUME; URINARY EXCRETION;

EID: 0036867247     PISSN: 09169636     EISSN: None     Source Type: Journal    
DOI: 10.1291/hypres.25.939     Document Type: Article

References (23)

1. Ecder T, Schrier RW: Hypertension in autosomal-dominant polycystic kidney disease: early occurrence and unique aspects. J Am Soc Nephrol 2001; 12: 194-200.
2. Hollenberg NK, Raij L: Angiotensin-converting enzyme inhibition and renal protection: an assessment of implications for therapy. Arch Intern Med 1993; 153: 2426-2435.
3. Epstein M: Calcium antagonists and renal protection. Arch Intern Med 1992; 152: 1573-1584.
4. Suzuki H, Moriwaki K, Kanno Y, Nakamoto H, Okada H, Chen XM: Comparison of the effects of an ACE inhibitor and alphabeta blocker on the progression of renal failure with left ventricular hypertrophy: preliminary report. Hypertens Res 2001; 24: 153-158.
5. Shionoiri H, Sugimoto K, Kosaka T, et al: Long-term therapy with an ACE inhibitor, temocapril, reduces microalbuminuria in essential hypertension. Hypertens Res 1998; 21: 81-87.
6. Rose GW, Kanno Y, lkebukuro H, et al: Clinidipine is as effective as benazepril for control of blood pressure and proteinuria in hypertensive patients with benign nephrosclerosis. Hypertens Res 2001; 24: 377-383.
7. Chapman AB, Johnson A, Gabow PA, Schrier RW: The renin-angiotensin-aldosterone -system and autosomal dominant polycystic kidney disease. N Engl J Med 1990; 323: 1091-1096.
8. Chapman AB, Gabow PA: Hypertension in autosomal dominant polycystic kidney disease. Kidney Int 1997; 61 (Suppl): S71-S73.
9. Cowley BD Jr, Gudapaty S, Kraybill AL, et al: Autosomal-dominant polycystic kidney disease in the rat. Kidney Int 1993; 43: 522-534.
10. Pfeffer JM, Pfeffer MA, Frohlich ED: Validity of an indirect tail-cuff method for determining systolic arterial pressure in unanesthetized normotensive and spontaneously hypertensive rat. J Lab Clin Med 1971; 78: 957-962.
11. Peterson GL: A simplification of the protein assay method of Lowry et al. which is more generally applicable. Anal Biochem 1977; 83: 346-356.
12. Ando Y, Moriyarna T, Oka K, et al: Enhanced interstitial expression of caldesmon in IgA nephropathy and its suppression by glucocorticoid-heparin therapy. Nephrol Dial Transplant 1999; 14: 1408-1417.
13. Wallenstein S, Zucker CL, Fleiss J: Some statistical methods useful on circulation research. Circ Res 1980; 47: 1-9.
14. Kaspareit-Rittinghausen J, Rapp K, Deerberg F, Wcislo A, Messow C: Hereditary polycystic kidney disease associated with osteorenal syndrome in rats. Vet Pathol 1989; 26: 195-201.
15. Keith DS, Torres VE, Johnson CM, Holley KE: Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis 1994; 24: 491-498.
16. Gile RD, Cowley BD Jr, Gattone VH II, O'Donnell MP, Swan SK, Grantham JJ: Effect of lovastatin on the development of polycystic kidney disease in the Han:SPRD rat. Am J Kidney Dis 1995; 26: 501-507.
17. Aukema HM, Housini I: Dietary soy protein effects on disease and IGF-I in male and female Han:SPRD-cy rats. Kidney Int 2001; 59: 52-61.
18. Kanno Y, Suzuki H, Okada H, Takenaka T, Saruta T: Calcium channel blockers versus ACE inhibitors as antihypertensives in polycystic kidney disease. QJM 1996; 89: 65-70.
19. Ogborn MR, Sareen S, Pinette G: Cilazapril delays progression of hypertension and uremia in rat polycystic kidney disease. Am J Kidney Dis 1995; 26: 942-946.
20. Kanno Y, Suzuki H, Okada H, Saruta T: Renal protective effects of amlodipine on partially nephrectomized spontaneously hypertensive rats fed a high-salt diet. J Cardiovasc Pharmacol 1994; 23: 480-484.
21. Shionoiri H, Kosaka T, Kita E, Takizawa T, Takasaki I: Comparison of long-term therapeutic effect of an ACE inhibitor, temocapril, with that of a diuretic on microalbuminuria in non-diabetic essential hypertension. Hypertens Res 2000; 23: 593-600.
22. Mori Y, Matsubara H, Nose A, et al: Safety and availability of doxazosin in treating hypertensive patients with chronic renal failure. Hypertens Res 2001; 24: 359-363.
23. Ecder T, Chapman AB, Brosnahan GM, Edelstein CL, Johnson AM, Schrier RW: Effect of antihypertensive therapy on renal function and urinary albumin excretion in hypertensive patients with autosomal dominant polycystic kidney disease. Am J Kidney Dis 2000; 35: 427-432.